Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

The RANGE study (NCT02426125) evaluated ramucirumab (an anti-VEGFR2 monoclonal antibody) in patients with platinum-refractory advanced urothelial carcinoma (UC). Here, we use programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) and transcriptome analysis to evaluate the association of i...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijden, Michiel S., Powles, Thomas, Petrylak, Daniel, de Wit, Ronald, Necchi, Andrea, Sternberg, Cora N., Matsubara, Nobuaki, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A., Bamias, Aristotelis, Gakis, Georgios, Lee, Jae-Lyun, Tagawa, Scott T., Vaishampayan, Ulka, Aragon-Ching, Jeanny B., Eigl, Bernie J., Hozak, Rebecca R., Rasmussen, Erik R., Xia, Meng Summer, Rhodes, Ryan, Wijayawardana, Sameera, Bell-McGuinn, Katherine M., Aggarwal, Amit, Drakaki, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987042/
https://www.ncbi.nlm.nih.gov/pubmed/35388003
http://dx.doi.org/10.1038/s41467-022-29441-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987042/
https://www.ncbi.nlm.nih.gov/pubmed/35388003
http://dx.doi.org/10.1038/s41467-022-29441-y

Ejemplares similares